Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Opaganib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RedHill's Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma
    RedHill's Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma

    26 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-opaganib-granted-orphan-drug-designation-by-the-fda-for-childhood-cancer-neuroblastoma-302230324.html

    PR NEWSWIRE
    26 Aug 2024
    Share Share
    RedHill Announces Positive Obesity and Diabetes Results with Opaganib
    RedHill Announces Positive Obesity and Diabetes Results with Opaganib

    19 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-positive-obesity-and-diabetes-results-with-opaganib-302225187.html

    PR NEWSWIRE
    19 Aug 2024
    Share Share
    RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040
    RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-a-new-patent-covering-opaganib-in-combination-with-immune-checkpoint-inhibitors-valid-through-2040-302161731.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    RedHill obtains Chinese patent for Opaganib against Ebola
    RedHill obtains Chinese patent for Opaganib against Ebola

    06 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-new-opaganib-chinese-patent-against-ebola-virus-valid-through-2035-302136648.html

    PR NEWSWIRE
    06 May 2024
    Share Share
    RedHill's Opaganib Selected for Evaluation by BARDA
    RedHill's Opaganib Selected for Evaluation by BARDA

    05 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-opaganib-selected-for-evaluation-by-barda-and-nih-countermeasures-programs-302079686.html

    PR NEWSWIRE
    05 Mar 2024
    Share Share
    RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation
    RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation

    20 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhills-opaganib-protects-against-radiation-induced-lung-inflammation-and-fibrosis--new-publication-302065891.html

    PR NEWSWIRE
    20 Feb 2024
    Share Share